Glucagon Dosing & Reconstitution Guide

Glucagon can be administered through various routes, including intramuscular (IM), subcutaneous (SC), intravenous (IV), or intranasal (as in Baqsimi). The frequency of administration is typically dictated by the clinical scenario, with doses given as needed during hypoglycemic emergencies or as a single dose for diagnostic purposes. The recommended dose range for emergency situations is generally 1 mg for adults via IM or SC routes, while children weighing less than 25 kg may receive 0.5 mg. For intranasal administration, Baqsimi is dosed at 3 mg. In diagnostic settings, doses can vary from 0.25 to 2 mg when administered intravenously or intramuscularly, depending on the specific requirements of the study or clinical evaluation.

The storage conditions for Glucagon vary based on its form. Lyophilized formulations, such as GlucaGen, should be stored at room temperature, ideally below 25 °C, to maintain stability. In contrast, Baqsimi requires storage below 30 °C and must not be refrigerated, as this could compromise its efficacy. Once reconstituted, Glucagon solutions should be used immediately. Research indicates that reconstituted solutions may not retain their potency over time, thus necessitating their immediate use to ensure accurate dosing during experimental procedures.

Common adverse effects associated with Glucagon administration include nausea and vomiting, which have been reported in 30-40% of cases following doses intended for hypoglycemia rescue. Additionally, transient hyperglycemia may occur post-administration. Baqsimi, the intranasal formulation, may lead to specific side effects such as nasal congestion, watery eyes, nasal itching, and upper respiratory tract irritation. Safety considerations are paramount, particularly in patients with certain contraindications. Glucagon is contraindicated in individuals with pheochromocytoma due to its potential to stimulate catecholamine release, leading to hypertensive crises. Insulinoma presents another risk, as glucagon may paradoxically exacerbate hypoglycemia by promoting insulin secretion. Furthermore, known hypersensitivity to glucagon or lactose should be taken into account, as some formulations contain lactose.